DPP4 and malignant mesothelioma: We have shown that administration of anti-CD26 mAb resulted in both in vitro and in vivo inhibition of tumor cell growth, migration and invasion, and enhanced survival of mouse xenograft models inoculated with T-lymphoma, renal cell carcinoma or malignant mesothelioma[14-16].